Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Head & Neck 1

Conditions

Solid Tumor, Adult 1Nasopharyngeal Carcinoma 1Advanced Cancer 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Valganciclovir × Clear all
NCT06391918 2026-03-13

Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors

GenVivo, Inc.

Phase 1 Terminated
37 enrolled
Other solid neoplasm

Solid Tumor, Adult

NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Viracta Therapeutics, Inc.

Phase 1 Terminated
26 enrolled 23 charts
Head & Neck

Nasopharyngeal Carcinoma

NCT06302140 2025-01-20

A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers

Viracta Therapeutics, Inc.

Phase 1 Terminated
8 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡